



Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

Sep 1, 2021

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

Events:

Morgan Stanley Virtual Annual Global Healthcare Conference

Format: Fireside Chat and investor 1x1 meetings

Thursday, September 9, 2021

11:45am ET

Please find a link to the presentation [here](#). A replay will be available for 90 days.

H.C. Wainwright 23rd Annual Global Investment Conference

Format: Presentation and investor 1x1 meetings

Monday, September 13, 2021

All company presentations will be available on-demand beginning at 7:00am ET

Please find a link to the presentation [here](#).

A webcast of both presentations can also be accessed under "Events & Presentations" in the Investors section of the Company's website, www.foghornrx.com

About Foghorn Therapeutics

Foghorn[®] Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control[®] platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavalié, Foghorn Therapeutics Inc.

fcavalié@foghornrx.com

Gregory Kelley, Ogilvy

gregory.kelley@ogilvy.com

Investor Relations Contact:

Ben Strain, Foghorn Therapeutics Inc.

bstrain@foghornrx.com

Hans Vitzthum, LifeSci Advisors

617-430-7578

hans@lifesciadvisors.com



Source: Foghorn Therapeutics, Inc.